Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nuvectis Pharma Inc

NVCT ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$20.89

▲ +0.92%

Market Cap $680.63M · Vol 43.44K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$680.63M

Small Cap

Div Yield

N/A

EPS Growth

+20.96%

YoY

RSI (14)

44.83

Momentum

Beta

-0.25

vs Market

52W High

$29.28

29.29% below

52W Low

$5.57

271.63% above

Volume

43.44K

Avg 78.21K

P/B

10.53

Price-to-book

ROE

N/A

Return on equity

Free Float

62.50%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Nuvectis Pharma Inc (NVCT) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NVCT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.35%

-9.17%

+8.29%

+136.85%

YTD

+176.69%

+252.87%

+132.11%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,442,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-105.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	10.53
P/FCF	N/A
EPS Growth	+20.96%
Outstanding Shares	32.58M

Technical Indicators

50-Day SMA	$21.70
200-Day SMA	$14.31
RSI (14)	44.83
Beta	-0.25
52-Week High	$29.28
52-Week Low	$5.57

Volume Today	43.44K
Avg Daily Volume (30D)	78.21K
Relative Volume	0.56x
Volatility (10D)	77.54
Volatility (30D)	70.53
Free Float	62.50%

Analyst Consensus

BUY

Current Price $20.89

Mean Target $35.40

52W Low$5.57 52W High$29.28

Current

Target

$5.57 $29.28

Current Analyst target

+69.46% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG012BCR158

ISINUS67080T1088

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.